Payment overview · 2025
General Payments
$859.42
50 reported records · 19 companies
Healthcare provider profile · identity verified
Seema Bir, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · RANCHO MIRAGE, CA · NPI 1720099294
Verified facts
What the public records show
CMS Open Payments records show Seema Bir, M.D. received $859.42 in general payments during 2025 across 50 reported records.
Amgen Inc. accounted for 26.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Prolia, Trelegy Ellipta, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Prolia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $223.40 | 26.0% | 23 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $67.47 | 7.8% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $64.15 | 7.5% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $58.84 | 6.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $47.14 | 5.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.43 | 5.4% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.38 | 5.4% | 2 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $29.03 | 3.4% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $28.95 | 3.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.09 | 3.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $27.89 | 3.2% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.81 | 3.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $27.69 | 3.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.31 | 3.2% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $27.26 | 3.2% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $25.95 | 3.0% | 1 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $23.61 | 2.8% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.19 | 1.9% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $15.83 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $859.42 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $132.38 | 13 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $132.38 | 13 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $91.02 | 10 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $64.15 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $58.84 | 3 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $47.14 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $46.43 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $46.38 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $41.27 | 6 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $32.08 | 1 | 2025 |
Source payment records
|
|||||
| Ormalvi Normalized: ormalvi |
Drug | Cycle Pharmaceuticals Inc | $29.03 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $28.95 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.09 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $27.89 | 1 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $27.81 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $27.69 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $27.31 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $27.26 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $25.95 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $25.95 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $15.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 69 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 125 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 37 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
42 | 16 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
69 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
125 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
122 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 591 | 199 |
| Amlodipine Besylate | Amlodipine Besylate | 576 | 189 |
| Levothyroxine Sodium | Levothyroxine Sodium | 549 | 184 |
| Losartan Potassium | Losartan Potassium | 350 | 114 |
| Metoprolol Succinate | Metoprolol Succinate | 293 | 100 |
| Lisinopril | Lisinopril | 285 | 94 |
| Gabapentin | Gabapentin | 266 | 96 |
| Alprazolam | Alprazolam | 251 | 70 |
| Metformin Hcl | Metformin Hcl | 209 | 82 |
| Omeprazole | Omeprazole | 193 | 66 |
| Valsartan | Valsartan | 161 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 159 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 155 | 59 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 147 | 57 |
| Potassium Chloride | Potassium Chloride | 145 | 56 |
| Zolpidem Tartrate | Zolpidem Tartrate | 133 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 131 | 53 |
| Tramadol Hcl | Tramadol Hcl | 127 | 44 |
| Ozempic | Semaglutide | 125 | 29 |
| Eliquis | Apixaban | 122 | 36 |
| Furosemide | Furosemide | 122 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 45 |
| Simvastatin | Simvastatin | 111 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 110 | 43 |
| Sertraline Hcl | Sertraline Hcl | 107 | 31 |
| Azithromycin | Azithromycin | 100 | 90 |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 34 |
| Carvedilol | Carvedilol | 97 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 96 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 96 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 93 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 90 | 74 |
| Trazodone Hcl | Trazodone Hcl | 89 | 27 |
| Lorazepam | Lorazepam | 88 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 83 | 28 |
| Atenolol | Atenolol | 82 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 75 | 24 |
| Glipizide | Glipizide | 73 | 22 |
| Alendronate Sodium | Alendronate Sodium | 72 | 24 |
| Allopurinol | Allopurinol | 72 | 29 |
| Estradiol | Estradiol | 69 | 27 |
| Mounjaro | Tirzepatide | 69 | 14 |
| Montelukast Sodium | Montelukast Sodium | 67 | 25 |
| Prednisone | Prednisone | 64 | 34 |
| Meloxicam | Meloxicam | 63 | 23 |
| Valacyclovir | Valacyclovir Hcl | 61 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 18 |
| Methylprednisolone | Methylprednisolone | 58 | 53 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 36 |
| Ezetimibe | Ezetimibe | 56 | 20 |
| Celecoxib | Celecoxib | 53 | 23 |
| Famotidine | Famotidine | 51 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 36 |
| Fenofibrate | Fenofibrate Nanocrystallized | 49 | 18 |
| Farxiga | Dapagliflozin Propanediol | 45 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 14 |
| Pregabalin | Pregabalin | 45 | 16 |
| Bupropion Xl | Bupropion Hcl | 44 | 13 |
| Januvia | Sitagliptin Phosphate | 44 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | 12 |
| Baclofen | Baclofen | 43 | 14 |
| Clonazepam | Clonazepam | 43 | 16 |
| Levetiracetam | Levetiracetam | 43 | suppressed |
| Temazepam | Temazepam | 43 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | 15 |
| Synthroid | Levothyroxine Sodium | 42 | 16 |
| Spironolactone | Spironolactone | 41 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 39 | 14 |
| Benazepril Hcl | Benazepril Hcl | 38 | 12 |
| Clonidine Hcl | Clonidine Hcl | 38 | 14 |
| Finasteride | Finasteride | 37 | 14 |
| Propranolol Hcl | Propranolol Hcl | 37 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | 11 |
| Jardiance | Empagliflozin | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 35 | 16 |
| Lovastatin | Lovastatin | 35 | 13 |
| Glimepiride | Glimepiride | 34 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | 17 |
| Chlorthalidone | Chlorthalidone | 30 | 13 |
| Amoxicillin | Amoxicillin | 29 | 24 |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 25 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 23 | 15 |
| Latanoprost | Latanoprost | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Ramipril | Ramipril | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 14 |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Lactulose | Lactulose | 22 | 13 |
| Lidocaine | Lidocaine | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 18 |
| Famciclovir | Famciclovir | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Clotrimazole | Clotrimazole | 19 | 14 |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Repatha Syringe | Evolocumab | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 18 | 11 |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Nystatin | Nystatin | 17 | 13 |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Progesterone | Progesterone, Micronized | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Erythromycin | Erythromycin Base | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Prolia | Denosumab | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 15 | suppressed |
| Methenamine Mandelate | Methenamine Mandelate | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Xifaxan | Rifaximin | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 13 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Piroxicam | Piroxicam | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $859.42 · 50 records | Amgen Inc. | APRETUDE, AREXVY, CONTRAVE, Cologuard Collection Kit, EVENITY, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, GIVLAARI, GVOKE HYPOPEN, Kerendia, MOUNJARO, NP Thyroid 60, OTEZLA, Ormalvi, Ozempic, PROLIA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VYNDAQEL, WATCHMAN FLX, Wegovy, XIFAXAN | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error